Researchers have solved a 50-year-old challenge in the production of doxorubicin, a critical chemotherapy drug used to treat over one million cancer patients annually. By engineering bacteria, the team achieved a 180% increase in yield compared to current manufacturing methods, addressing molecular bottlenecks that have forced pharmaceutical companies to rely on expensive, multi-step processes since the 1970s.
The breakthrough, detailed in a recent study, focuses on the biosynthetic pathway of doxorubicin. Scientists identified and modified key enzymes in the bacterium Streptomyces peucetius to enhance production of the drug. This approach overcomes limitations that have constrained output for decades, potentially reducing costs and improving supply reliability.
Doxorubicin is widely used in chemotherapy for various cancers, including breast, bladder, and lung cancers. Despite its efficacy, manufacturing has been inefficient, leading to high prices and occasional shortages. The new method could streamline production, making the drug more accessible to patients worldwide.
Industry observers note that the innovation may influence other cancer drug developers. Companies like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are likely to monitor these developments closely, as they represent a significant advancement in biotechnology.
The research team plans to further optimize the bacterial strain for industrial-scale production. If successful, the technology could be licensed to pharmaceutical manufacturers, potentially transforming the doxorubicin market.
For more information on the study, readers can refer to the original publication. This advancement underscores the potential of synthetic biology to address long-standing pharmaceutical challenges.
